Crossmark

The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance—study protocol for a randomized 4-way balanced cross-over trial

Crossref DOI link: https://doi.org/10.1186/s13063-021-05862-w

Published Online: 2021-12-11

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zügel, Martina

Bizjak, Daniel A.

Nussbaumer, Dorle

Winkert, Kay

Takabayashi, Kensuke

Kirsten, Johannes

Washington, Mickel

Treff, Gunnar

Dreyhaupt, Jens

Steeb, Luise

Diel, Patrick

Parr, Maria Kristina

Steinacker, Jürgen M.

Persch, Hasema
Funding

Funding for this research was provided by:

world anti-doping agency - research grant (15C13MZ)

Universitätsklinikum Ulm
License Information

Text and Data Mining valid from 2021-12-01

Version of Record valid from 2021-12-11
More Information

Article History

Received: 6 July 2021

Accepted: 22 November 2021

First Online: 11 December 2021

Declarations

:

: The ELSA trial was approved by the ethics committee of Ulm University, Germany (reference number: 64/19). Participants were informed by medical staff about the study protocol and received a copy of the study information before obtaining signed consent and inclusion into the study.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below